Food News and Research

RSS

Standards of hygiene may also contribute to development of auto-immune diseases in children

The incidence of auto-immune diseases like type 1 diabetes and allergies has risen dramatically in developed countries over the past fifty years. The reasons for this trend are not fully understood but a theory known as the 'hygiene hypothesis' links it to a rise in hygiene standards.

9 Jan 2014

Merck announces FDA approval of ISENTRESS for oral suspension

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration recently approved ISENTRESS for oral suspension, a new pediatric formulation of Merck's integrase inhibitor. With this approval, ISENTRESS is now indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in patients four weeks of age and older.

9 Jan 2014

Study explores relationship between avocado consumption, satiety and blood sugar

New research published in the November issue of Nutrition Journal reports adding one-half of a fresh avocado to a lunch may have helped healthy, overweight people feel more satisfied and reduced their desire to eat following a meal. The study was funded by the Hass Avocado Board.

9 Jan 2014

Proteon's PRT-201 gets orphan drug designation for prevention of arteriovenous access dysfunction

Proteon Therapeutics, Inc., a privately held biopharmaceutical company developing novel, first-in-class pharmaceuticals to address the critical medical needs of patients with kidney and vascular diseases, today announced that its lead product, PRT-201, has received orphan drug designation in the European Union for the prevention of arteriovenous access dysfunction in hemodialysis patients.

9 Jan 2014

FDA approves Actavis' ANDA for Telmisartan Immediate-Release Tablets

Actavis plc today announced that it has received approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application for Telmisartan Immediate-Release Tablets, 20 mg, 40 mg and 80 mg, a generic equivalent to Boehringer Ingelheim's Micardis. Actavis intends to launch the product immediately.

9 Jan 2014

C. parvum and cryptosporidiosis: an interview with Dr. Momar Ndao, McGill University

Cryptosporidium parvum is one of the most common enteropathogens to affect humans in the world. The protozoan parasite causes a gut infection referred to as cryptosporidiosis.

8 Jan 2014

Emmaus completes all patient visits for Phase 3 trial of L-glutamine for treatment of sickle cell disease

Emmaus Medical, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of innovative and cost-effective treatments and therapies primarily for rare and orphan diseases, today announced it has completed all patient visits for its Phase 3 clinical trial for the treatment of sickle cell disease. Emmaus expects top-line data from the Phase 3 clinical trial to be available in the first quarter of 2014.

8 Jan 2014

FDA completes inspection of LSNE's medical device manufacturing facility in Manchester

Lyophilization Services of New England, a New Hampshire based contract manufacturing organization is pleased to announce that the Food and Drug Administration recently completed an inspection of their Manchester manufacturing facility.

8 Jan 2014

Veterans who played varsity sports during high school stay fit and healthy at 70

Fit and healthy 70 year olds who don't frequently visit the doctor have something unexpected in common - they played varsity sports in high school.

8 Jan 2014

Insight Genetics receives $1.5M SBIR contract to research on resistance mutations in NSCLC patients

Insight Genetics, Inc. today announced it has received a new $1.5 million Phase II Small Business Innovation Research contract from the National Cancer Institute.

8 Jan 2014

CytoDyn receives FDA approval to start Phase 2b study of PRO 140 for treatment of HIV-1

CytoDyn Inc., a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today the Company has received approval from the United States Food and Drug Administration (FDA) to commence patient screening of a Phase 2b study of PRO 140, a monoclonal CCR5 antibody, for the treatment of patients with Human Immunodeficiency Virus Type 1.

8 Jan 2014

Fetal exposure to Bisphenol A can increase risk for prostate cancer later in life

Fetal exposure to a commonly used plasticizer found in products such as water bottles, soup can liners and paper receipts can increase the risk for prostate cancer later in life, according to a study from the University of Illinois at Chicago published Jan. 7 online in the journal Endocrinology.

8 Jan 2014

10 simple points to know and monitor alcohol intake

Much the same way individuals are encouraged to know their blood pressure and cholesterol numbers to maintain a healthy lifestyle, a new editorial in the Journal of Psychopharmacology urges the European public to know and monitor their alcohol intake number using a simple 10 point plan.

7 Jan 2014

Study sheds light on the biological underpinnings of obesity

A new neuroscience study sheds light on the biological underpinnings of obesity. The in vivo study, published in the January 8 issue of the Journal of Neuroscience, reveals how a protein in the brain helps regulate food intake and body weight. The findings reveal a potential new avenue for the treatment of obesity and may help explain why medications that are prescribed for epilepsy and other conditions that interfere with this protein, such as gabapentin and pregabalin, can cause weight gain.

7 Jan 2014

First patient enrolled in the North American Phase 3 clinical trials for investigational flu treatment drug

BioDefense Therapeutics—a Joint Product Management office within the U.S. Department of Defense—announced the first patient enrolled in the North American Phase 3 clinical trials for favipiravir (T-705a). The drug is an investigational flu treatment candidate with broad-spectrum potential being developed by BD Tx through a contract with Boston-based MediVector, Inc.

7 Jan 2014

FDA accepts NPS Pharmaceuticals' Natpara BLA for review

NPS Pharmaceuticals, Inc., a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today announced that the U.S. Food and Drug Administration has accepted and filed for review the company's Biologics License Application for Natpara (recombinant human parathyroid hormone 1-84, (rhPTH[1-84])) for the treatment of hypoparathyroidism.

7 Jan 2014

Mylan launches Tolterodine Tartrate ER Capsules, 2 mg and 4 mg

Mylan Inc. today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Tolterodine Tartrate Extended-release Capsules, 2 mg and 4 mg. Tolterodine Tartrate ER Capsules are the generic version of Pfizer's Detrol LA, and are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product.

7 Jan 2014

Fruit smoothies visibly improve skin's appearance

A group of university students are enjoying a specially designed fruit smoothie a day to discover whether it can improve their appearance and make them feel healthier.

7 Jan 2014

LabStyle Innovations files 510(k) with FDA for Dario Blood Glucose Monitoring System

LabStyle Innovations Corp., developer of Dario, a cloud-based, mobile health platform for diabetes and blood glucose monitoring, announced today that it has filed a Premarket Notification Application, also known as a 510(k), with the US Food and Drug Administration for the Dario Blood Glucose Monitoring System.

7 Jan 2014

FDA OOPD grants orphan drug designation to Alitair's Erdosteine for treatment of bronchiectasis

Alitair Pharmaceuticals, Inc., today announced that the Office of Orphan Products Development of the Food and Drug Administration has granted orphan drug designation for its drug candidate, Erdosteine, for the treatment of bronchiectasis. Erdosteine is a mucolytic with antibacterial, anti-inflammatory, and antioxidant properties.

7 Jan 2014

Food News and Research

Standards of hygiene may also contribute to development of auto-immune diseases in children

Merck announces FDA approval of ISENTRESS for oral suspension

Study explores relationship between avocado consumption, satiety and blood sugar

Proteon's PRT-201 gets orphan drug designation for prevention of arteriovenous access dysfunction

FDA approves Actavis' ANDA for Telmisartan Immediate-Release Tablets

C. parvum and cryptosporidiosis: an interview with Dr. Momar Ndao, McGill University

Emmaus completes all patient visits for Phase 3 trial of L-glutamine for treatment of sickle cell disease

FDA completes inspection of LSNE's medical device manufacturing facility in Manchester

Veterans who played varsity sports during high school stay fit and healthy at 70

Insight Genetics receives $1.5M SBIR contract to research on resistance mutations in NSCLC patients

CytoDyn receives FDA approval to start Phase 2b study of PRO 140 for treatment of HIV-1

Fetal exposure to Bisphenol A can increase risk for prostate cancer later in life

10 simple points to know and monitor alcohol intake

Study sheds light on the biological underpinnings of obesity

First patient enrolled in the North American Phase 3 clinical trials for investigational flu treatment drug

FDA accepts NPS Pharmaceuticals' Natpara BLA for review

Mylan launches Tolterodine Tartrate ER Capsules, 2 mg and 4 mg

Fruit smoothies visibly improve skin's appearance

LabStyle Innovations files 510(k) with FDA for Dario Blood Glucose Monitoring System

FDA OOPD grants orphan drug designation to Alitair's Erdosteine for treatment of bronchiectasis

Enhancing confidence in chemical ionization spectrometry data eBook

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News